4basebio (LON:4BB – Get Free Report) issued its earnings results on Monday. The company reported GBX (0.57) earnings per share (EPS) for the quarter, Digital Look Earnings reports.
4basebio Stock Down 0.5%
4basebio stock traded down GBX 2.70 during mid-day trading on Tuesday, reaching GBX 559.80. 261 shares of the company were exchanged, compared to its average volume of 1,353. The company has a debt-to-equity ratio of 201.47, a quick ratio of 3.52 and a current ratio of 2.73. The firm has a market cap of £86.69 million, a P/E ratio of -5.14 and a beta of 1.09. The business has a fifty day moving average of GBX 511.05 and a 200 day moving average of GBX 510.01. 4basebio has a 12-month low of GBX 420 and a 12-month high of GBX 820.
Analyst Ratings Changes
Separately, Royal Bank Of Canada lowered their target price on shares of 4basebio from GBX 1,600 to GBX 1,400 and set an “outperform” rating on the stock in a research note on Monday, June 15th. One equities research analyst has rated the stock with a Buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of GBX 1,400.
About 4basebio
4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients.
Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients. These products and technologies are also available for customers and partners with whom we endeavor to combine our capabilities and know-how to develop gene therapy solutions for clinical development and commercialisation.
Read More
- Five stocks we like better than 4basebio
- Bottlenecking the Future: TSMC Prices Out the Competition
- Fervo Energy Hits Geothermal Milestone: Will It Matter For The Stock?
- Tesla’s Semi Is Finally Here—But Will It Move the Stock?
- 5 Stocks Showing Why Pricing Power Matters More Than Government Money
Receive News & Ratings for 4basebio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 4basebio and related companies with MarketBeat.com's FREE daily email newsletter.
